April 27, 2021 11:43 AM EDTUpdated 11:56 AM

Eli Lilly shares take a hit as company lowers full-year forecast

Nicole DeFeudis

Editor

The rollout of Covid-19 vaccines and the decision to halt distribution of its antibody therapy has left Eli Lilly with some disappointing news to share …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly shares take a hit as company lowers full-year forecast

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Eli Lil­ly shares take a hit as com­pa­ny low­ers full-year fore­cast

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Eli Lilly shares take a hit as company lowers full-year forecast